Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

14.67 +0.07 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 176,809
Open 14.47
Bid (Size) 13.40 (1,000)
Ask (Size) 16.04 (200)
Prev. Close 14.60
Today's Range 14.45 - 15.05
52wk Range 12.56 - 25.00
Shares Outstanding 54,902,942
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Pulse Biosciences, Inc.
Via Business Wire

Performance

YTD
+9.6%
+9.6%
1 Month
+8.7%
+8.7%
3 Month
-26.2%
-26.2%
6 Month
-5.5%
-5.5%
1 Year
-23.4%
-23.4%

More News

Read More
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences (PLSE) Earnings Transcript ↗
Via The Motley Fool
News headline image
Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Cash Jumps in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Pulse Biosciences Inc (NASDAQ:PLSE) Reports Q2 2025 Earnings: Wider Loss, Clinical Progress in Focus ↗
Via Chartmill
News headline image
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 12, 2025 ↗
Via Benzinga

Frequently Asked Questions

Is Pulse Biosciences, Inc - Common Stock publicly traded?
Yes, Pulse Biosciences, Inc - Common Stock is publicly traded.
What exchange does Pulse Biosciences, Inc - Common Stock trade on?
Pulse Biosciences, Inc - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pulse Biosciences, Inc - Common Stock?
The ticker symbol for Pulse Biosciences, Inc - Common Stock is PLSE on the Nasdaq Stock Market
What is the current price of Pulse Biosciences, Inc - Common Stock?
The current price of Pulse Biosciences, Inc - Common Stock is 14.67
When was Pulse Biosciences, Inc - Common Stock last traded?
The last trade of Pulse Biosciences, Inc - Common Stock was at 01/06/26 04:00 PM ET
What is the market capitalization of Pulse Biosciences, Inc - Common Stock?
The market capitalization of Pulse Biosciences, Inc - Common Stock is 805.43M
How many shares of Pulse Biosciences, Inc - Common Stock are outstanding?
Pulse Biosciences, Inc - Common Stock has 805M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.